INmune Bio: Thinking Through XPro's MINDFuL Data In Early Alzheimer's

Core Insights - INmune Bio (NASDAQ: INMB) has been part of the "Bio Boom" speculative portfolio since September 2023, with no changes made to its position despite the company's progress [2] Group 1 - The company has not seen any adjustments in its investment thesis since its inclusion in the portfolio [2] - The leader of the investing group Compounding Healthcare focuses on innovative companies developing breakthrough therapies and pharmaceuticals [2] Group 2 - The analyst holds a beneficial long position in INMB shares, indicating confidence in the company's potential [3]